Home LiteratureArticle Details
PMID: 6227099 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Relationships among the complement, kinin, coagulation, and fibrinolytic systems.

Springer seminars in immunopathology ·Vol. 6 ·No. 2-3 ·1983-00-00 ·Pages 231-58

Sundsmo JS, Fair DS

Abstract

暂无摘要

MeSH Terms
Blood Coagulation Blood Platelets/physiology Complement Activation Complement System Proteins/physiology Fibrin/physiology Fibrinolysin/physiology Fibrinolysis Humans Kallikreins/physiology Kinins/physiology Leukocytes/physiology Thrombin/physiology
Chemicals
Kinins Fibrin Complement System Proteins Kallikreins Thrombin Fibrinolysin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sundsmo J S
Fair D S
References (189)
189 references, click to expand
  1. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).
    J Exp Med. 1974 Sep 1;140(3):797-811 PMID: 4378413
  2. Blood coagulation initiation by a complement-mediated pathway.
    J Exp Med. 1971 Dec 1;134(6):1601-7 PMID: 5166613
  3. [Studies on the problem of blood coagulation disorder in the Sanarelli-Shwartzman phenomena (so-called generalized Shwartzman phenomenon) of the rabbit].
    Z Gesamte Exp Med. 1959;132:275-94 PMID: 14409739
  4. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration.
    J Clin Invest. 1979 Jun;63(6):1302-6 PMID: 447844
  5. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.
    J Exp Med. 1971 Apr 1;133(4):696-712 PMID: 4251126
  6. Production of blood coagulation factor V and tissue thromboplastin by macrophages in vitro.
    FEBS Lett. 1981 May 5;127(1):154-60 PMID: 7250370
  7. Interaction of fibronectin with C1q and its collagen-like fragment (CLF).
    FEBS Lett. 1981 Jun 29;129(1):188-92 PMID: 6974103
  8. The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator.
    J Clin Invest. 1973 Oct;52(10):2591-5 PMID: 4729052
  9. The conversion of C'IS to C'1 esterase by plasmin and trypsin.
    J Exp Med. 1967 Feb 1;125(2):337-58 PMID: 4225264
  10. STUDIES ON THE PATHOGENESIS OF THE GENERALIZED SHWARTZMAN REACTION. II. ROLE PLAYED BY EXPERIMENTALLY INDUCED FIBRINOLYSIS.
    Thromb Diath Haemorrh. 1964 Dec 31;12:462-70 PMID: 14254704
  11. Disappearance of fibrinogen-131-I after endotoxin: effects of a first and second injection.
    Am J Physiol. 1968 Mar;214(3):532-7 PMID: 5638985
  12. Zymogens and cofactors of blood coagulation.
    CRC Crit Rev Biochem. 1980;9(1):45-85 PMID: 6777115
  13. A plasminogen proactivator-activator system in human blood effective in absence of Hageman Factor.
    Thromb Res. 1974 Apr;4(4):609-13 PMID: 4428468
  14. Quantitative aspects of blood coagulation in the generalized Shwartzman reaction. II. Effect of cortisone.
    Pediatr Res. 1967 Mar;1(2):99-103 PMID: 5339831
  15. Clevage of human Clś by human lysosomal enzymes, plasmin, and trypsin.
    Immunochemistry. 1971 Oct;8(10):951-61 PMID: 4261121
  16. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.
    J Exp Med. 1969 Feb 1;129(2):315-31 PMID: 4178758
  17. Leukocyte complement: assembly of the membrane attack complex of complement by human peripheral blood leukocytes in the presence and absence of serum.
    J Immunol. 1978 Mar;120(3):855-60 PMID: 416143
  18. Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures.
    J Exp Med. 1967 Jul 1;126(1):149-58 PMID: 4226164
  19. Genetics and biosynthesis of complement proteins.
    N Engl J Med. 1981 Mar 12;304(11):653-6 PMID: 6450325
  20. Purification and partial characterization of plasminogen activator from human uterine tissue.
    Biochim Biophys Acta. 1979 Sep 29;580(1):140-53 PMID: 121055
  21. Human deficiency of the sixth component of complement in a patient with meningococcal meningitis and no haemostasis abnormality.
    Biomedicine. 1980;33(6):197-201 PMID: 6783144
  22. Properties of sulfatides in factor-XII-dependent contact activation.
    Blood. 1982 Jan;59(1):69-75 PMID: 6914902
  23. A functional differentiation of human neutrophil granules: generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products.
    J Immunol. 1977 Sep;119(3):1068-76 PMID: 19531
  24. The relation of 'Fletcher Factor' to factors XI and XII.
    Br J Haematol. 1970 Feb;18(2):161-9 PMID: 5439523
  25. The pathogenetic role of the coagulation process in glomerular diseases of immunologic origin.
    Adv Nephrol Necker Hosp. 1971;1:47-63 PMID: 4143241
  26. C1 and human platelets. III. Role of C1 subcomponents in platelet aggregation induced by aggregated IgG.
    Immunology. 1976 Oct;31(4):595-9 PMID: 185144
  27. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.
    J Biol Chem. 1979 Mar 25;254(6):1998-2003 PMID: 106053
  28. Platelet activation: a new biological activity of guinea-pig C3a anaphylatoxin.
    Scand J Immunol. 1978;7(2):173-80 PMID: 653315
  29. Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway.
    J Clin Invest. 1982 Mar;69(3):564-72 PMID: 6916769
  30. The leukocyte complement system.
    Fed Proc. 1982 Dec;41(14):3094-8 PMID: 7141004
  31. Further link between complement activation and blood coagulation.
    Nature. 1977 Nov 10;270(5633):173-4 PMID: 927528
  32. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.
    J Lab Clin Med. 1970 Nov;76(5):809-15 PMID: 5477337
  33. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.
    J Clin Invest. 1973 Jun;52(6):1402-9 PMID: 4703226
  34. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
    J Clin Invest. 1970 Nov;49(11):2068-85 PMID: 4248913
  35. First component of complement and thrombosis.
    Thromb Haemost. 1981 Jun 30;45(3):247-51 PMID: 7281103
  36. Platelet requirement in the interaction of the complement and clotting systems.
    Nat New Biol. 1972 Oct 18;239(94):208-10 PMID: 4117161
  37. Fibrinogen degradation products in serum and urine of patients with systemic lupus erythematosus. Relation to renal disease and pathogenetic mechanism.
    Arthritis Rheum. 1971 Mar-Apr;14(2):267-75 PMID: 5549972
  38. In vitro studies of immunologically induced secretion of mediators from cells and related phenomena.
    Adv Immunol. 1973;17:93-193 PMID: 4131638
  39. Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis.
    J Immunol. 1973 Aug;111(2):536-45 PMID: 4268733
  40. Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. Characterization and effects on blood coagulation in vitro.
    J Clin Invest. 1978 Apr;61(4):1027-33 PMID: 77863
  41. The human complement system in thrombin-mediated platelet function.
    J Exp Med. 1978 Jun 1;147(6):1713-26 PMID: 681879
  42. Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury.
    J Exp Med. 1975 Jun 1;141(6):1261-8 PMID: 805209
  43. The role of phospholipids and factor Va in the prothrombinase complex.
    J Biol Chem. 1980 Jan 10;255(1):274-83 PMID: 7350159
  44. Human platelet-initiated formation and uptake of the C5-9 complex of human complement.
    J Clin Invest. 1976 Jan;57(1):203-11 PMID: 812888
  45. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement.
    J Immunol. 1982 Jun;128(6):2505-8 PMID: 7077078
  46. Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes.
    J Clin Invest. 1977 Mar;59(3):549-57 PMID: 190271
  47. Mechanisms of lipopolysaccharide-initiated rabbit platelet responses: alternative complement pathway dependence of the lytic response.
    Infect Immun. 1978 Jun;20(3):744-51 PMID: 352956
  48. Mechanism of action of factor D of the alternative complement pathway.
    J Exp Med. 1978 Dec 1;148(6):1498-509 PMID: 82604
  49. Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets.
    J Immunol. 1974 Dec;113(6):1744-51 PMID: 4610046
  50. Complement-induced vascular leukostasis. Its role in tissue injury.
    Arch Pathol Lab Med. 1980 Dec;104(12):617-20 PMID: 6893656
  51. Effects of bacterial endotoxin on rabbit platelets. II. Enhancement of platelet factor 3 activity in vitro and in vivo.
    J Exp Med. 1962 Nov 1;116:619-33 PMID: 13954979
  52. Reactive haemolysis--a distinctive form of red cell lysis.
    Immunology. 1968 May;14(5):745-62 PMID: 4172980
  53. Blood coagulation and the inflammatory response.
    Semin Hematol. 1977 Oct;14(4):391-408 PMID: 144322
  54. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.
    J Biol Chem. 1982 Mar 25;257(6):2912-9 PMID: 7199524
  55. THE PRESENCE OF TWO PERMEABILITY GLOBULINS IN HUMAN SERUM.
    J Clin Invest. 1963 Aug;42:1353-61 PMID: 14057861
  56. Complement fragments, alveolar macrophages, and alveolitis.
    Am J Pathol. 1979 Oct;97(1):93-110 PMID: 495697
  57. Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus.
    J Clin Invest. 1976 Jul;58(1):142-51 PMID: 932202
  58. Plasminogen activation by normal B lymphocytes, a function associated with the cell membrane.
    J Immunol. 1981 Mar;126(3):1126-30 PMID: 6161960
  59. Tissue factor generation by human mononuclear cells: effects of endotoxin and dissociation of tissue factor generation from mitogenic response.
    J Lab Clin Med. 1977 Apr;89(4):792-803 PMID: 321714
  60. Synthesis and secretion of complement proteins by macrophages.
    Ann N Y Acad Sci. 1979;332:482-90 PMID: 394641
  61. The relation of CIsa, a subunit of the activated first component of complement, to other plasma enzymes.
    Biochim Biophys Acta. 1973 Nov 15;327(1):207-12 PMID: 4272357
  62. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.
    J Allergy. 1962 Jul-Aug;33:330-41 PMID: 14461960
  63. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.
    J Exp Med. 1969 May 1;129(5):1109-30 PMID: 5778786
  64. Demonstration of high-affinity binding sites for C3a anaphylatoxin on guinea-pig platelets.
    Scand J Immunol. 1978;8(6):551-5 PMID: 734357
  65. The role of human T cells (and T cell products) for monocyte tissue factor generation.
    J Immunol. 1980 Aug;125(2):606-9 PMID: 6967082
  66. Aggregation and release reaction induced in human blood platelets by zymosan.
    J Immunol. 1974 Mar;112(3):1219-30 PMID: 4811967
  67. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.
    J Biol Chem. 1977 Sep 10;252(17):6097-104 PMID: 408348
  68. Neutrophil chemotaxis in response to surface-bound C5A.
    Exp Cell Res. 1980 Sep;129(1):55-62 PMID: 7428814
  69. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit.
    J Immunol. 1980 Jun;124(6):2919-24 PMID: 7373056
  70. The activation of the alternative pathway C3 convertase by human plasma kallikrein.
    Immunology. 1982 Mar;45(3):587-95 PMID: 6916710
  71. The prevention of the generalized Shwartzman reaction by fibrinolytic activity.
    AMA Arch Pathol. 1958 Dec;66(6):715-9 PMID: 13593967
  72. Affinity isolation and characterization of immunoglobulin G Fc fragment-binding glycoprotein from human blood platelets.
    J Biol Chem. 1979 Apr 10;254(7):2165-7 PMID: 429275
  73. Studies on the generalized Shwartzman reaction: I. General observations concerning the phenomenon.
    J Exp Med. 1952 Dec;96(6):605-24 PMID: 13022854
  74. The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide.
    J Immunol. 1981 Jul;127(1):357-63 PMID: 6165771
  75. Studies on the mechanism of inactivation of human complement by plasmin and by antigen-antibody aggregates. I. The requirement for a factor resembling C'1 and the role of Ca++.
    J Immunol. 1954 Sep;73(3):146-58 PMID: 13201755
  76. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.
    J Immunol. 1982 Jun;128(6):2500-4 PMID: 6281332
  77. Degenerative vascular disease and myocardial infarction in mice with lupus-like syndrome.
    Am J Pathol. 1979 Aug;96(2):477-92 PMID: 474707
  78. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit.
    J Exp Med. 1981 Jun 1;153(6):1391-404 PMID: 6910482
  79. Biologically active peptides derived from the fifth component of complement.
    Prog Hemost Thromb. 1980;5:41-79 PMID: 6999532
  80. Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen.
    J Immunol. 1981 Sep;127(3):877-80 PMID: 6911148
  81. Limited degradation of the third component (C3) of human complement by human leukocyte elastase (HLE): partial characterization of C3 fragments.
    Biochemistry. 1977 Jul 26;16(15):3390-6 PMID: 889803
  82. Macrophages produce blood coagulation factors.
    FEBS Lett. 1980 Oct 20;120(1):41-3 PMID: 7439388
  83. Factor B of the alternative complement pathway on human lymphocytes.
    Scand J Immunol. 1976;5(6-7):697-704 PMID: 824718
  84. Mononuclear cell tissue factor: cell of origin and requirements for activation.
    Blood. 1979 Aug;54(2):359-70 PMID: 454843
  85. Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation.
    Immunology. 1977 Jun;32(6):929-40 PMID: 328387
  86. In vitro stimulation of tissue thromboplastin (factor III) activity in human monocytes by immune complexes and lectins.
    Thromb Res. 1979;15(3-4):465-74 PMID: 494155
  87. Prekallikrein and plasminogen proactivator: absence of plasminogen proactivator in Fletcher factor deficient plasma.
    Thromb Res. 1976 Apr;8(4):519-22 PMID: 1273811
  88. Cold activation of complement i. presence of coagulation-related activator.
    J Immunol. 1976 Aug;117(2):486-90 PMID: 59781
  89. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator.
    J Exp Med. 1972 Dec 1;136(6):1378-93 PMID: 4264575
  90. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro.
    J Clin Invest. 1981 Jun;67(6):1614-22 PMID: 7240410
  91. Responses of human platelets to immunologic stimuli: independent roles for complement and IgG in zymosan activation.
    J Immunol. 1978 Jan;120(1):9-14 PMID: 627728
  92. Modulation of the immune response by anaphylatoxin in the microenvironment of the interacting cells.
    Fed Proc. 1982 Dec;41(14):3099-103 PMID: 6216123
  93. Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity.
    J Immunol. 1975 Dec;115(6):1505-8 PMID: 1184964
  94. Cyclic AMP and platelet function.
    N Engl J Med. 1972 Feb 17;286(7):358-63 PMID: 4333462
  95. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator.
    J Biol Chem. 1982 Mar 25;257(6):2920-5 PMID: 7199525
  96. Stimulation of human leukocyte thromboplastic activity by endotoxin.
    Proc Soc Exp Biol Med. 1971 Oct;138(1):145-8 PMID: 4942184
  97. Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells.
    Am J Pathol. 1979 Jan;94(1):75-83 PMID: 569981
  98. Secretion of plasminogen activator by stimulated macrophages.
    J Exp Med. 1974 Apr 1;139(4):834-50 PMID: 4816302
  99. C1 inactivator inhibition by plasmin.
    J Clin Invest. 1970 Mar;49(3):568-75 PMID: 4244455
  100. Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection.
    N Engl J Med. 1980 Jul 31;303(5):259-63 PMID: 6900901
  101. Inactivation of human serum plasminogen antiactivator by synthetic fibrinolysis inducers.
    Thromb Diath Haemorrh. 1969 Nov 15;22(2):251-62 PMID: 4985767
  102. STUDIES ON THE PATHOGENESIS OF THE GENERALIZED SHWARTZMAN REACTION. I. ALTERATIONS IN THE COAGULATION SYSTEM DURING THE GENERALIZED SHWARTZMAN REACTION OF THE PREGNANT RABBIT.
    Thromb Diath Haemorrh. 1964 Dec 31;12:452-61 PMID: 14254703
  103. Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response.
    Adv Immunol. 1969;10:145-227 PMID: 4242699
  104. Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reactions.
    J Immunol. 1975 Jan;114(1 Pt 2):377-87 PMID: 1090656
  105. Chemical characterization of human factor B of the alternate pathway of complement activation.
    Biochemistry. 1977 Nov 29;16(24):5368-75 PMID: 411505
  106. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.
    J Exp Med. 1970 Aug 1;132(2):329-52 PMID: 4101346
  107. Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. II. The effects of zymosan.
    J Immunol. 1974 Mar;112(3):1211-8 PMID: 4590701
  108. Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex.
    J Exp Med. 1979 Sep 19;150(3):633-45 PMID: 479764
  109. Complement.
    Annu Rev Biochem. 1975;44:697-724 PMID: 1094920
  110. Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice.
    J Exp Med. 1981 Oct 1;154(4):1150-63 PMID: 6270227
  111. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.
    J Exp Med. 1965 Aug 1;122:327-46 PMID: 14316948
  112. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein.
    Proc Natl Acad Sci U S A. 1981 Apr;78(4):2512-6 PMID: 6454142
  113. Biologial effects of the human complement fragments C5a and C5ades Arg on neutrophil function.
    Immunopharmacology. 1980 Jun;2(3):201-19 PMID: 6254906
  114. [The plasminogen-plasmin system. 8. On the mechanism of chemical induction of fibrinolysis. Isolation of a latent plasminogen activator from human plasma].
    Thromb Diath Haemorrh. 1973 Feb 28;29(1):50-62 PMID: 4267738
  115. Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. I. Complement-dependent and complement-independent reactions.
    J Immunol. 1974 Mar;112(3):1201-10 PMID: 4811966
  116. The proteolytic activation systems of complement.
    Annu Rev Biochem. 1981;50:433-64 PMID: 7023363
  117. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation.
    J Clin Invest. 1979 Jan;63(1):147-50 PMID: 762243
  118. Role of complement and leukocytes in immunologic release of vasoactive amines from platelets.
    Fed Proc. 1969 Sep-Oct;28(5):1721-8 PMID: 4185893
  119. The blood clotting properties of rabbit peritoneal leukocytes in vitro.
    Thromb Diath Haemorrh. 1967 Feb 28;17(1-2):222-36 PMID: 5584955
  120. Activation of the classical pathway of complement by Hageman factor fragment.
    J Exp Med. 1981 Mar 1;153(3):665-76 PMID: 7252410
  121. Evidence for C1 on human platelets.
    Haemostasis. 1973-1974;2(6):281-6 PMID: 4213101
  122. Coagulation as a common thread in disease.
    Science. 1982 Oct 8;218(4568):145-6 PMID: 7123225
  123. Coagulant activity of leukocytes. Tissue factor activity.
    J Clin Invest. 1972 Feb;51(2):307-13 PMID: 4333021
  124. Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses.
    J Clin Invest. 1973 May;52(5):1282-8 PMID: 4700496
  125. Third component of human complement: structural analysis of the polypeptide chains of C3 and C3b.
    Biochemistry. 1979 Apr 17;18(8):1497-503 PMID: 427127
  126. Blood coagulation.
    Annu Rev Biochem. 1980;49:765-811 PMID: 6996572
  127. Activation of plasminogen by human plasma kallikrein.
    Biochem Biophys Res Commun. 1969 Apr 29;35(2):273-9 PMID: 4239105
  128. Lymphocyte cooperation is required for amplification of macrophage procoagulant activity.
    J Exp Med. 1980 May 1;151(5):1232-44 PMID: 7373220
  129. Platelet-dependent generation of chemotactic activity in serum.
    J Exp Med. 1973 Jun 1;137(6):1419-30 PMID: 4709268
  130. Structure and function of membrane complement receptors. Summary.
    Fed Proc. 1982 Dec;41(14):3089-93 PMID: 6982833
  131. C1q (c1) receptor on human platelets: inhibition of collagen-induced platelet aggregation by C1q (C1) molecules.
    J Immunol. 1976 Jul;117(1):304-9 PMID: 1084367
  132. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor).
    J Immunol. 1981 Sep;127(3):1250-5 PMID: 6267133
  133. Alterations in the blood coagulation system induced by bacterial endotoxins. II. In vitro.
    J Exp Med. 1958 Mar 1;107(3):369-76 PMID: 13513906
  134. The occurrence of leucocyte-platelet thrombosis in rheumatic carditis.
    J Exp Med. 1951 Dec 1;94(6):493-500 PMID: 14897995
  135. Factors influencing platelet function: adhesion, release, and aggregation.
    Pharmacol Rev. 1970 Jun;22(2):97-187 PMID: 4192958
  136. Essential role of surface-bound chemoattractant in leukocyte migration.
    Nature. 1977 Nov 24;270(5635):351-2 PMID: 563519
  137. A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6.
    J Exp Med. 1971 Dec 1;134(6):1591-600 PMID: 5126641
  138. Region of the Clq molecule involved in the interaction between platelets and subcomponent Clq of the first component of complement.
    Mol Immunol. 1980 Nov;17(11):1399-405 PMID: 7464837
  139. Interaction of plasma kallikrein with the C1 inhibitor.
    J Immunol. 1970 Mar;104(3):574-81 PMID: 5435787
  140. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH.
    J Clin Invest. 1975 Jul;56(1):30-8 PMID: 237938
  141. Human complement in the arachidonic acid transformation pathway in platelets.
    J Exp Med. 1981 Feb 1;153(2):257-68 PMID: 7241047
  142. Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets.
    N Engl J Med. 1979 Jan 18;300(3):106-11 PMID: 569254
  143. A plasmin-split fragment of C'3 as a new chemotactic factor.
    J Exp Med. 1967 Aug 1;126(2):189-206 PMID: 4226271
  144. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.
    Thromb Haemost. 1980 Jun 18;43(2):77-89 PMID: 6450468
  145. Studies on the mode of reaction of the first component of complement with platelets: interaction between the collagen-like portion of C1q and platelets.
    Immunochemistry. 1977 Nov-Dec;14(11-12):763-6 PMID: 202559
  146. The effects of aggregated immunoglobulins on human blood platelets in relation to their complement-fixing abilities. I. Studies of immunoglobulins of different types.
    J Immunol. 1972 Sep;109(3):517-25 PMID: 5066345
  147. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: two procoagulant activities are produced by peripheral blood mononuclear cells.
    J Clin Invest. 1981 Jun;67(6):1650-8 PMID: 7240413
  148. Normal and abnormal hemostasis--an integrated view. A review.
    Am J Pathol. 1978 Sep;92(3):775-812 PMID: 686158
  149. Clq inhibition of the interaction of collagen with human platelets.
    J Immunol. 1976 Jan;116(1):162-3 PMID: 1245737
  150. Role of complement in endotoxin initiated lethality in mice.
    Immunopharmacology. 1979 Mar;1(2):125-35 PMID: 400473
  151. The inactivation of complement and its components by plasmin.
    J Exp Med. 1953 Apr;97(4):573-89 PMID: 13052820
  152. Immune complex-induced human monocyte procoagulant activity. I. a rapid unidirectional lymphocyte-instructed pathway.
    J Exp Med. 1981 Sep 1;154(3):892-906 PMID: 7276829
  153. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a.
    Crit Rev Immunol. 1981 Feb;1(4):321-66 PMID: 7037298
  154. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice.
    Eur J Cancer. 1980 Jul;16(7):919-23 PMID: 7000518
  155. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.
    Am J Med. 1963 Jul;35:37-44 PMID: 14046003
  156. Complement (Clq), polyanions and platelet activation.
    Thromb Res. 1980 Aug 15-Sep 1;19(4-5):729-31 PMID: 6777900
  157. Factor V.
    Methods Enzymol. 1981;80 Pt C:249-74 PMID: 7043191
  158. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Inflammation. 1981 Dec;5(4):263-73 PMID: 6976935
  159. Immunological characterization of plasminogen activator activities in human tissues and body fluids.
    J Lab Clin Med. 1981 Apr;97(4):477-86 PMID: 6782183
  160. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.
    J Biol Chem. 1981 Jul 10;256(13):7035-41 PMID: 6787058
  161. A re-appraisal of the role of blood coagulation and platelets in the generalized shwartzman phenomenon.
    Thromb Diath Haemorrh. 1966 May 15;15(3):519-38 PMID: 5989035
  162. Limited proteolysis of C5b-6: functional stability of the degraded complex.
    J Immunol. 1980 Jan;124(1):332-6 PMID: 6444229
  163. Alterations in the blood coagulation system induced by bacterial endotoxin. I. In vivo (generalized Shwartzman reaction).
    J Exp Med. 1958 Mar 1;107(3):353-67 PMID: 13513905
  164. Platelet-serotonin release by C3a and C5a: two independent pathways of activation.
    J Immunol. 1981 Apr;126(4):1506-9 PMID: 7204973
  165. Plasma inhibitors of the components of the fibrinolytic pathway in man.
    J Clin Invest. 1973 Jun;52(6):1394-401 PMID: 4122174
  166. Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A.
    J Clin Invest. 1973 Jun;52(6):1427-34 PMID: 4634046
  167. Role of leukocytes in blood coagulation and the generalized Shwartzman reaction.
    Nat New Biol. 1971 Aug 25;232(34):247-8 PMID: 5286196
  168. Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.
    J Immunol. 1983 Jun;130(6):2605-11 PMID: 6602172
  169. Mechanisms of release of constituents from rabbit platelets by antigen-antibody complexes and complement. I. Lytic and nonlytic reactions.
    J Immunol. 1970 Aug;105(2):476-89 PMID: 5433702
  170. Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement.
    J Exp Med. 1975 Dec 1;142(6):1570-90 PMID: 1104750
  171. Studies on the activation of a proesterase associated with partially purified first component of human complement.
    J Exp Med. 1958 Mar 1;107(3):451-74 PMID: 13513912
  172. Molecular mechanism of physiological fibrinolysis.
    Nature. 1978 Apr 6;272(5653):549-50 PMID: 151233
  173. Platelet aggregation and release of ADP, serotonin and histamine associated with phagocytosis of antigen-antibody complexes.
    Proc Soc Exp Biol Med. 1965 Oct;120(1):232-7 PMID: 4159017
  174. Platelet activating factor (PAF). A possible direct mediator of anaphylaxis in the rabbit and a trigger for the vascular deposition of circulating immune complexes.
    Monogr Allergy. 1977;12:13-26 PMID: 335211
  175. Studies on the fourth component of complement. II. The fourth component of complement in guinea pig and human platelets.
    Biken J. 1965 Sep;8(3):129-41 PMID: 5861684
  176. C1 and human platelets. II. Detection by immunological methods and role.
    Immunology. 1976 Apr;30(4):459-65 PMID: 818006
  177. Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells.
    J Immunol. 1980 Oct;125(4):1658-64 PMID: 7410850
  178. The induction of macrophage spreading: role of coagulation factors and the complement system.
    J Exp Med. 1976 Dec 1;144(6):1531-44 PMID: 1003102
  179. Inability of a highly purified streptokinase preparation to inactivate complement in serum.
    Acta Pathol Microbiol Scand. 1965;64(3):318-28 PMID: 5855583
  180. An effect of antigen-antibody interaction on blood coagulation.
    J Exp Med. 1959 Jan 1;109(1):1-8 PMID: 13611160
  181. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.
    J Exp Med. 1970 Apr 1;131(4):643-57 PMID: 4193935
  182. The chemotactic activity for neutrophil and eosinophil leucocytes of the trimolecular complex of the fifth, sixth and seventh components of human complement (C567) prepared in free solution by the 'reactive lysis' procedure.
    Immunology. 1970 Dec;19(6):895-9 PMID: 5487541
  183. Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis.
    J Clin Invest. 1974 Feb;53(2):554-8 PMID: 11344569
  184. The ability of chemotactic factors to induce lysosomal enzyme release. I. The characteristics of the release, the importance of surfaces and the relation of enzyme release to chemotactic responsiveness.
    J Immunol. 1974 Jun;112(6):2047-54 PMID: 4596695
  185. Thrombin and complement: lack of reactivity of purified bovine and human thrombin on components of the complement system.
    Immunol Commun. 1973;2(5):473-81 PMID: 4757432
  186. Biosynthesis of complement components.
    Fed Proc. 1981 May 15;40(7):2099-104 PMID: 7227564
  187. Effects of granulocyte neutral proteases on complement components.
    Scand J Immunol. 1976;5(4):421-6 PMID: 181839
  188. The effects of bacterial endotoxins on host mediation systems. A review.
    Am J Pathol. 1978 Nov;93(2):526-618 PMID: 362943
  189. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro.
    J Exp Med. 1968 Mar 1;127(3):411-29 PMID: 5299945
Article Info
Journal
Springer seminars in immunopathology
Abbr.
Springer Semin Immunopathol
ISSN
0344-4325
DOI
10.1007/BF00205875
Published
1983-00-00
Pages
231-58
Language
English
Region
Germany
NLM ID
7910384
Subset
IM
Grants
NHLBI NIH HHS · HL-16411-08 · United States
NIAID NIH HHS · R01-AI-17890 · United States
NHLBI NIH HHS · R01-HL-28672 · United States
External Links
PubMed source DOI: 10.1007/BF00205875
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2